Dalcor Pharmaceuticals Is A Biopharmaceutical Company Focused On Addressing Cardiovascular Diseasea Major Global Health Challengethe Company Specializes In Developing Precision Pharmacogenetic Medicineparticularly For Patients With The Aa Genotype At The Rs1967309 Location In The Adcy9 Gene The Main Product Offered By Dalcor Is Dalcetrapiba Precision Medicine Aimed At Reducing The Risk Of Fatal And Non Fatal Myocardial Infarction In Patients With Post Acute Coronary Syndrome Who Have The Adcy9 Aa Genotypedalcetrapib Is Currently Being Evaluated In The Dal Gene 2 Phase 3 Clinical Trial To Confirm Its Efficacy In Improving Cardiovascular Outcomesadditionallydalcor Has Developed A Companion Diagnostic Test In Collaboration With Roche Molecular Systems To Identify Suitable Patients For This Treatment Dalcor Pharmaceuticals Is Committed To Advancing Cardiovascular Health Through Innovative Research And Clinical Trialswith A Focus On Genetically Targeted Therapiesthe Company Has Secured Significant Funding To Support Its Ongoing Projects And Is Actively Engaged In Partnerships To Enhance Its Capabilities In The Field
